TY - JOUR
T1 - Mantle cell lymphoma
T2 - The promise of new treatment options
AU - Goy, Andre
AU - Kahl, Brad
N1 - Funding Information:
The authors received editorial support in the preparation of this manuscript, funded by Celgene Corporation. The authors were fully responsible for content and editorial decisions for this manuscript.
PY - 2011/10
Y1 - 2011/10
N2 - Though the expected overall survival (OS) for mantle cell lymphoma (MCL) has doubled in the last 30 years it is still in the range of only 4-5 years. Despite high response rates with current first-line treatments, most patients eventually relapse and become typically chemoresistant, leading to very poor outcome in the relapsed setting. Here, we summarize the clinical characteristics of MCL and frontline strategies used in MCL, and review a number of novel options that are currently being investigated in an effort to extend survival outcomes for this difficult-to-treat patient population. Among these novel options figure cytotoxics (bendamustine, cladribine), new biologicals/small molecules such as proteasome inhibitors (bortezomib 1st drug approved in the USA for MCL), mTOR inhibitors with temsirolimus (1st drug approved in EU for MCL), CDK inhibitors (flavopiridol); IMiDs (thalidomide, lenalidomide); HDAC inhibitors, Bcl-2 inhibitors and second or third generation monoclonal antibodies or immunotoxins. The panel of novel drugs approved or being tested offers new opportunities in the management of MCL from combination in the frontline setting (e.g. bortezomib-R-chemo) to post-induction strategies such as consolidation (e.g. radioimmunotherapy, bortezomib) or maintenance therapy (e.g. rituximab, lenalidomide).
AB - Though the expected overall survival (OS) for mantle cell lymphoma (MCL) has doubled in the last 30 years it is still in the range of only 4-5 years. Despite high response rates with current first-line treatments, most patients eventually relapse and become typically chemoresistant, leading to very poor outcome in the relapsed setting. Here, we summarize the clinical characteristics of MCL and frontline strategies used in MCL, and review a number of novel options that are currently being investigated in an effort to extend survival outcomes for this difficult-to-treat patient population. Among these novel options figure cytotoxics (bendamustine, cladribine), new biologicals/small molecules such as proteasome inhibitors (bortezomib 1st drug approved in the USA for MCL), mTOR inhibitors with temsirolimus (1st drug approved in EU for MCL), CDK inhibitors (flavopiridol); IMiDs (thalidomide, lenalidomide); HDAC inhibitors, Bcl-2 inhibitors and second or third generation monoclonal antibodies or immunotoxins. The panel of novel drugs approved or being tested offers new opportunities in the management of MCL from combination in the frontline setting (e.g. bortezomib-R-chemo) to post-induction strategies such as consolidation (e.g. radioimmunotherapy, bortezomib) or maintenance therapy (e.g. rituximab, lenalidomide).
KW - Bendamustine
KW - Bortezomib
KW - Flavopiridol
KW - Lenalidomide
KW - Mantle cell lymphoma
KW - Non-Hodgkin's lymphoma
KW - Rituximab
KW - Temsirolimus
UR - http://www.scopus.com/inward/record.url?scp=80053131089&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2010.09.003
DO - 10.1016/j.critrevonc.2010.09.003
M3 - Review article
C2 - 21168343
AN - SCOPUS:80053131089
SN - 1040-8428
VL - 80
SP - 69
EP - 86
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - 1
ER -